Reston, VA (August 22, 2025)—New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
Summaries of the newly published research articles are provided below.
Mapping Tiny Lifetimes with Big Impact
Scientists tested a new imaging approach called positronium lifetime tomography using a specialized scanner and radioactive tracers. By capturing ultra-fine differences in particle lifetimes within a 3D model, they achieved millimeter-level resolution. This technique could open the door to sharper, more detailed medical scans in the future.
New Imaging Targets for Endometrial Cancer
Researchers explored three biomarkers—HER2, MUC16, and CD24—as potential guides for advanced imaging in endometrial cancer. Using specially designed PET probes in lab and mouse models, they found that HER2- and CD24-targeted probes produced strong tumor signals, highlighting promising new avenues for diagnosing and tracking this growing disease.
Imaging Advances for Cushing Disease
Cushing disease is often caused by tiny pituitary tumors that are difficult to detect with MRI alone. In this multicenter study, researchers tested 11C-methionine PET/MRI in patients before surgery. The combined scan showed high accuracy in localizing tumors, offering valuable insights for improving diagnosis and guiding treatment strategies.
Testing a New Therapy for Sarcoma
Sarcoma patients face limited treatment options, but researchers explored a targeted radiotherapy called 177Lu-DOTAGA.Glu.(FAPi)2. In this study, 10 patients received multiple treatment cycles, which were generally well tolerated. Imaging showed promising signs of tumor control in some patients, suggesting this approach may offer hope for difficult-to-treat cancers.
Visit the JNM website for the latest research, and follow our new Twitter and Facebook pages @JournalofNucMed or follow us on LinkedIn .
